Clinical trial NCT03784456: Impact of Increased Protein Density Diet to Muscle Mass and Strength Among Mid-aged and Older Adults
Official title: Impact of Increased Protein Density Diet to Muscle Mass and Strength Among Mid-aged and Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Loss
Muscle Weakness
Fragility
Lead sponsor: National Yang Ming Chiao Tung University
Sponsor class: OTHER
Collaborators: name: Laurel Corporation, Taiwan
First posted: 2018-12-24
Enrollment: 70
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This program is designed as a double blind parallel randomized intervention. The primary purpose of this program is Prevention.
Primary purpose: PREVENTION

Brief summary: The subjects of this intervention program are mainly based on community-dwelling mid-aged and older adults. The investigator's program will provide meals containing different proportionated protein.As this project is a double blind test, only the investigators will know which subject corresponding to specific group of diets.

Besides, the investigators use the valued-based healthcare standard set as well as the Center for Epidemiological Studies-Depression, Charlson's comorbidity index Montreal Cognitive Assesment ,and Mini Nutritional Assessment as outcome measures and to use the randomized controlled trial design to validate if increased protein density diet could improve the vitality and health of mid-aged and old adults .

Detailed description: With aging, functions of every organs become to decline. Muscle mass, is one of the decline. According to previous research, adults would lose 40% among from aged 20 to 70. If muscle mass decline combining with the decline of muscle strength is so called Sarcopenia.When muscle mass decline, infectious risk gets higher, and resilience after illness gets lower. In addition, activity and life quality are also responsible for falling, cognitive difficulty, disability and mortality among seniors. We hope to find out the etiologies of Sarcopenia through this program and develop prevention strategy and model to mollify the the negative effect of rapid aging society.

Eligibility criteria: Inclusion Criteria:

* People who aged 40-75 years
* Patients with following characteristics:
* feeling loss in activity
* detecting decline in self's walking speed.
* feeling tired of doing everything.
* having fell in last year.
* People can accept undergoing MRI
* People willing to follow the program and cooperate with us for following tracking.
* People who are neither vegan nor vegetarian
* People agree and be able to sign the informed consent.

Exclusion Criteria:

* People cannot intake provided meals (e.g.: vegans or vegetarians) or any other who is allergic to our diets.
* People with any disease affecting their limbs, including:
* having fracture on limbs in the past 6 months
* having severe arthritis in the past 6 months
* any other whom PI recognized as weak control of their nervous system( e.g.: Parkinson's disease and stroke).
* People with intermittent limp caused by peripheral artery diseases
* People with weak control of mental disorder
* People with weak control of Cardiopulmonary disease
* People with weak control of Malignant tumor
* People with weak control of kidney diseases (eGFR \<60ml/min/1.73)
* People with Visual impairment and Hearing disorder which cannot help to complete the program.
* People who are unable to undertake MRI
* People who have underwent hormone treatment and planned to undergo hormone treatment during program session.
* Any other condition that PI recognized as not suitable

Primary outcomes:
measure: Changes from baseline muscle strength after 12 weeks
timeFrame: baseline,12 weeks
measure: Changes form baseline QUALITY OF LIFE after 12 weeks
timeFrame: baseline, 12 weeks
measure: Change from baseline Nutrition intake after 12 weeks
timeFrame: baseline, 12 weeks.
measure: Change from baseline depression after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline cognitive ability after 12 weeks
timeFrame: baseline, 12 weeks
measure: Change from baseline endurance after 12 weeks
timeFrame: baseline, 12 weeks
measure: Change from baseline walking speed after 12 weeks
timeFrame: baseline, 12 weeks
measure: Change from baseline timed up and go test after 12 weeks
timeFrame: baseline, 12 weeks
Secondary outcomes:
measure: Change from baseline numbers of Complete blood count after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of Albumin after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of blood urea nitrogen after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of Creatinin after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of Fasting glucose after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of Fasting insulin after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of Total Cholesterol after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of Triglyceride after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of dehydroepiandrosterone after 12 weeks
timeFrame: baseline,12 weeks
measure: Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks
timeFrame: baseline, 12 weeks
measure: Change from baseline concentration of Leptin after 12 weeks
timeFrame: baseline, 12 weeks
measure: Change from baseline concentration of urine protein after 12 weeks
timeFrame: baseline, 12 weeks
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Yang Ming University
Study officials:
affiliation: Aging and Health Research Center, National Yang Ming University
name: Liang-Kung Chen, MD.PhD.
role: PRINCIPAL_INVESTIGATOR
References: